WO2005041873A3 - Formulation of exendin-4 - Google Patents

Formulation of exendin-4 Download PDF

Info

Publication number
WO2005041873A3
WO2005041873A3 PCT/US2004/035088 US2004035088W WO2005041873A3 WO 2005041873 A3 WO2005041873 A3 WO 2005041873A3 US 2004035088 W US2004035088 W US 2004035088W WO 2005041873 A3 WO2005041873 A3 WO 2005041873A3
Authority
WO
WIPO (PCT)
Prior art keywords
exendin
articles
methods
formulation
articles made
Prior art date
Application number
PCT/US2004/035088
Other languages
French (fr)
Other versions
WO2005041873A2 (en
Inventor
Stephen C Rowe
Durga Annavajjula
Original Assignee
Azopax Therapeutics Llc
Stephen C Rowe
Durga Annavajjula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azopax Therapeutics Llc, Stephen C Rowe, Durga Annavajjula filed Critical Azopax Therapeutics Llc
Publication of WO2005041873A2 publication Critical patent/WO2005041873A2/en
Publication of WO2005041873A3 publication Critical patent/WO2005041873A3/en
Priority to US11/410,269 priority Critical patent/US20070053954A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Abstract

The invention provides methods and articles for the administration of exendin-4. These methods and articles provide for the controlled and sustained delivery of relatively large quantities of exendin-4 with a low burst effect. The articles made using the method of the invention have increased percentages (w/w) of macromer, increased crosslinking density, and reduced pore size in comparison to articles made using solution methods.
PCT/US2004/035088 2003-10-24 2004-10-25 Formulation of exendin-4 WO2005041873A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/410,269 US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51424303P 2003-10-24 2003-10-24
US60/514,243 2003-10-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/410,269 Continuation-In-Part US20070053954A1 (en) 2003-10-24 2006-04-24 Macromer-melt formulations

Publications (2)

Publication Number Publication Date
WO2005041873A2 WO2005041873A2 (en) 2005-05-12
WO2005041873A3 true WO2005041873A3 (en) 2005-07-21

Family

ID=34549321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035088 WO2005041873A2 (en) 2003-10-24 2004-10-25 Formulation of exendin-4

Country Status (1)

Country Link
WO (1) WO2005041873A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773293B1 (en) 2004-06-17 2015-04-15 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating central precocious puberty
EP2457564A1 (en) 2005-03-11 2012-05-30 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
EP2347762B1 (en) 2005-08-19 2019-05-08 Amylin Pharmaceuticals, LLC Exendin for treating diabetes and reducing body weight
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
RU2463079C2 (en) 2007-04-27 2012-10-10 Эндо Фармасьютикалз Солюшнз Инк. Separation agents for implanted device and methods for using them
EP2187934A1 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of fertirelin and delta-endorphin as therapeutic agents
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
WO2009158412A2 (en) 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
KR20110025974A (en) 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. Octreotide implant having a release agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
WO2005041873A2 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
AU2003273259A1 (en) Drug cartridge assembly and method of manufacture
WO2005025499A3 (en) Hydrophobic drug compositions containing reconstitution enhancer
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2007011874A3 (en) Formulation and method for administration of ophthalmologically active agents
WO2004060460A3 (en) Medical devices with cutting element.
WO2005044224A3 (en) Drug delivery system based on polymer nanoshells
WO2006042230A8 (en) Medical devices and methods of making the same
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
HK1087031A1 (en) Subcutaneous implants having limited initial release of the active principle and subsequent linearlyvarying extended release thereof
WO2005053784A3 (en) Lead stabilization devices and methods
WO2009083544A3 (en) Pdgf fusion proteins incorporated into fibrin foams
WO2005099667A3 (en) Drug delivery compositions
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2008005873A3 (en) Methods, systems and apparatus for relieving pressure in an organ
WO2005009356A3 (en) Method for the preparation of controlled release formulations
WO2005108428A3 (en) Cd40 splice variants and their uses
WO2001070197A3 (en) Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
AU2003304420A8 (en) Compositions, methods, apparatuses, and systems for singlet oxygen delivery
AU2003213425A1 (en) Vaporizer, various devices using the same, and vaporizing method
WO2004087043A3 (en) Stable ophthalmic formulation containing an antibiotic and a corticosteroid
WO2005041873A3 (en) Formulation of exendin-4
WO2005107753A3 (en) Naltrexone long acting formulations and methods of use
AU2002254942A1 (en) Paracetamol solutions which are stable in storage and ready for infusion
WO2005082781A3 (en) Method for preparing adjustably bioresorbable sol-gel derived sio2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11410269

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 11410269

Country of ref document: US